| Literature DB >> 24486383 |
Kuo-Hsuan Chang1, Wan-Ling Chen1, Yih-Ru Wu1, Te-Hsien Lin2, Yi-Ci Wu2, Chih-Ying Chao1, Jung-Yaw Lin3, Li-Ching Lee2, Yi-Chun Chen1, Guey-Jen Lee-Chen4, Chiung-Mei Chen5.
Abstract
Spinocerebellar ataxias (SCAs), caused by expanded CAG repeats encoding a long polyglutamine (polyQ) tract in the respective proteins, are characterized by the accumulation of intranuclear and cytoplasmic misfolded polyQ aggregation that leads to cell death. Suppression of aggregate formation can inhibit a wide range of downstream pathogenic events and is expected to be a therapeutic strategy for SCAs. Here we show the anti-aggregation potential of Gardenia jasminoides (G. jasminoides) and its components/metabolite geniposide, crocin, and genipin, in ATXN3/Q75-GFP 293 cells, a putative SCA3 cell model. We found the aggregation can be significantly prohibited by G. jasminoides, genipin, geniposide and crocin. Meanwhile, G. jasminoides, genipin, geniposide, and crocin up-regulated anti-oxidative markers NFE2L2, NQO1, GCLC and GSTP1, and reduced the production of reactive oxidative species (ROS) in the same cell models. All of them further inhibited the aggregation in neurally differentiated SH-SY5Y ATXN3/Q75-GFP cells. Our results demonstrate that G. jasminoides, genipin, geniposide and crocin work on polyQ-aggregation reduction by suppressing ROS. These findings indicate the therapeutic applications of G. jasminoides in treating SCAs. Furthermore, oxidative stress inhibition could be a good target for drug development of anti-polyQ aggregation.Entities:
Keywords: ATXN3; Gardenia jasminoides; NFE2L2; Oxidative stress; Spinocerebellar ataxia
Mesh:
Substances:
Year: 2014 PMID: 24486383 DOI: 10.1016/j.neuropharm.2014.01.032
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250